Multi-tenant SaaS digital validation platform that digitizes the full validation lifecycle — authoring, execution, review, approval, and audit handover — for GxP-regulated life sciences organizations, with no-code configurability supporting both document-centric and data-centric ("Entities") validation.
Kneat Gx (vendor: Kneat Solutions, TSX: KSI / OTCQX: KSIOF) is a Validation Lifecycle Management (VLMS) platform covering Commissioning & Qualification (C&Q/CQV), Computer System Validation (CSV) / Computer Software Assurance (CSA), Equipment Validation, Process Validation, Cleaning Validation, Cold Chain Validation, Analytical/Lab Instrument Validation, Test Method Validation, Facilities & Utilities Validation, eLogbooks, Electronic Batch Records, Document Management, and Drawing Management.
Founded in 2007 in Limerick, Ireland by pharmaceutical-sector engineers; first enterprise rollout 2015. Reported FY2025 ARR C$74.1M (35% YoY growth), SaaS revenue growth 33%, Net Revenue Retention 115%. Headcount 300+ employees. Single SKU sold into Pharma, Biotech, Medical Device, Consumer Health, and CDMO segments. Current GA release: 25-R3 track on 9.x SaaS 3.0 architecture, extended by Kneat AI ("GRID" model) for AI features released within Kneat Gx in 2025.
Positioning: "any validation process, your way, in one platform." G2 ranked Kneat Gx #1 in the Fall 2025 Grid for Pharma & Biotech Software with a 98/100 satisfaction score. Kneat reports use by 8 of the world's top 10 life-sciences companies; a later vendor page revises the figure to 9 of 10. On 2026-05-11, the Board confirmed formation of a special committee with CIBC Capital Markets to review strategic alternatives, a process that carries change-of-control risk for customers under multi-year contracts signed during the review.
Core Capabilities
FDA & GxP Compliance
International Standards
Security Certifications
Data Integrity & Validation
SaaS-only, multi-tenant on AWS with separate US and EU SaaS regions. No on-premise option. SaaS 3.0 architecture (introduced with v9.0) uses Kubernetes (Amazon EKS) with containerized workloads, multi-AZ clusters, dynamic scaling, infrastructure-as-code via HashiCorp Terraform/Packer/Consul/Vault, and 15-minute RPO. AWS WAF and DDoS protection front the platform; AWS Redshift and QuickSight for analytics/dashboards.
Browser-based access only (modern evergreen browsers). No native mobile applications publicly listed. SSO supported; specific protocol/IdP matrix (SAML, OIDC, AzureAD, Okta) not publicly enumerated. MFA added in v25-R3. REST APIs for import/export of documents, drawings, and data; big-data APIs mentioned as part of AI initiative; GraphQL, webhooks, rate limits, and SDK availability not publicly documented. Named pre-built productized connectors are NOT listed — integrations delivered via SI partners (Capgemini strategic partnership announced January 2025, CAI) or custom API work. Users cite integration gaps as a friction point. Data residency: US and EU regions; AWS GovCloud/China/India not listed.
Subscription SaaS recognized as recurring SaaS license + maintenance ARR. Investor materials describe a "land-and-expand" model with site-by-site expansion. Multi-year terms typical (3-year MSAs commonly announced). Whether licensing is per named user, per concurrent user, per-tenant, per-site, or consumption-based is not publicly disclosed.
Pricing transparency: no starting price published; enterprise quoted-pricing only. No public free trial; demo available via "Book a demo" form. Reported deal sizes: not publicly disclosed at granularity. FY2025 ARR C$74.1M across the customer base predominantly enterprise life sciences; FY2025 added "nine major strategic wins" representing 300,000+ employees collectively. Mid-six to seven-figure annual deals for top-20 pharma and major CDMO segments reported; smaller for biotech. Minimum commitments, setup fees, validation-support fees not publicly disclosed.
Vendor-published average implementation: 8-12 weeks regardless of segment. Enterprise multi-site rollouts run longer; MSAs with global manufacturers typically describe phased site-by-site expansion after a lead site. Kneat provides a consulting/professional services arm (process assessment, system configuration, training, validation strategy, change management, data migration, managed services); pricing of services vs. license not disclosed publicly.
Kneat Academy offers tiered eLearning and certification (End User → Power User 1 → Power User 2). Migration: Excel/CSV via REST APIs and Document Management module (mass uploads, mass approvals, bulk export); explicit migration from existing CMS/DMS named, but no productized migrators from paper or other platforms. Common pitfalls: slow performance on very large protocols; steep learning curve for non-validation users; integration limitations with adjacent enterprise systems; global rollouts require disciplined template/Entity harmonization governance.
Anonymous feedback from pharmaceutical professionals using this solution
4.5 out of 5
Based on 97 verified reviews
What Users Like
Users consistently report rapid implementation, intuitive authoring, fast review/approval cycles, and material reductions in validation cycle time. "Kneat Gx has transformed validation from a document-driven process into a data-driven workflow. Real-time execution and parallel review has significantly reduced cycle times." Published customer case studies: 50%+ cycle time reduction (MSD, Sanofi, ElevateBio), 46% test script time savings (Fujirebio Diagnostics), 88% URS approval-cycle reduction. 97% of customers rate support "Very Good" or "Excellent". NPS above 70 (vendor-stated).
What Users Dislike
Users cite three recurring frictions: (1) performance on large protocols / occasional latency ("Kneat can sometimes be slow to load and occasionally glitches during document workflows"); (2) integration gaps with adjacent enterprise systems ("Data availability and shareability… need improvement as Kneat seems to lack a good solution for interfacing with other tools"); (3) learning curve for new users and administrators ("the learning curve can be steep — especially for users who are new to digital validation systems"). No published SOC 2 Type II report, no ISO 13485 vendor certification, no FedRAMP/GovCloud option.
Help the community
Share your experience with Kneat Gx anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackPublicly disclosed pharmaceutical and biotech organizations
Jump to section